Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
Carter
C
C
Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK.
Winfield
D A
DA
D000328:Adult; D000677:Amsacrine / Q000009:adverse effects* / Q000627:therapeutic use; D001803:Blood Transfusion; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000627:therapeutic use; D005164:Factor IX / Q000627:therapeutic use; D005170:Factor X / Q000627:therapeutic use; D005171:Factor X Deficiency / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D007020:Hypoprothrombinemias / Q000139:chemically induced*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local; D011516:Prothrombin / Q000627:therapeutic use; D011517:Prothrombin Time
D000677:Amsacrine; D005047:Etoposide; D011516:Prothrombin; D005164:Factor IX; D005170:Factor X